Back to School: Clarity Clinic Psychiatrist Speaks Out On the Child & Adolescent Mental Health Crisis
24 août 2022 12h30 HE
|
Clarity Clinic
CHICAGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- As the summer months come to a close, many young students prepare to head back to school. Although this time can be filled with excitement, the crisis in...
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
12 nov. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
01 nov. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant...
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
24 oct. 2018 08h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release...
Neos Therapeutics to Present Two Posters on Company’s ADHD Medications at the American Academy of Child & Adolescent Psychiatry Meeting
24 oct. 2017 16h21 HE
|
Neos Therapeutics, Inc.
DALLAS/FORT WORTH, Texas, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS) today announced that it will present two posters at the 64th Annual Meeting of the American Academy...
Neos Therapeutics Presents Data for Investigational ADHD Treatment Cotempla XR-ODT at AACAP's 62nd Annual Meeting
30 oct. 2015 16h01 HE
|
Neos Therapeutics, Inc.
DALLAS/FORT WORTH, Texas, October 30, 2015 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with three late-stage proprietary, extended release (XR) product...